Cardiovascular diseases



资源 13

Product Introduction

B1448 is intended to treat Acute Pulmonary Embolism and its mechanism of action is the same as that of PUK for treating STEMI.

Potential Advantages

(1) The new generation of fibrin-specific thrombolytic drug, with a unique mechanism of thrombolysis, low risk of systemic bleeding, and great safety;
(2) Low rate of re-thrombosis after thrombolysis;
(3) Advanced manufacturing process, and affordable to the patients; PUK has been covered in the National Reimbursed Drug List (NRDL) three times in a row.
Clinical Progress

B1448 Phase II clinical trial was completed.